Medical Developments International Limited · ASX:MVP
Medical Developments International — Investor Presentation (September 2004)
17 slides from Medical Developments International's investor presentation, Sep 1, 2004
Slide 1: Medical Developments International Limited Presentation
Medical Developments International Limited (“MDI’) Presentation September 2004
Slide 2: Profile of Business
S a 8 i & rai s s oD 2 ae oD E ee 2 S o ‘2 © 2 G2 wo S Profile of Business =» Three business segments + Pharmaceutical (Penthrox) Medical Equipment * Veterinary Equipment = Manufacturing plant & operations located in Springvale, Melbourne = Plantis GMP Certified = Product Registrations + Penthrox re
Slide 3: FY04 Highlights
5 a 8 © & rai s s oD 2 ae oD E ee 2 S o ‘2 © 2 G2 wo S FY04 Highlights €> «" Smooth transition of customers from MDA to MDI « Annualised FY04 NPAT of $1.2m (pre amortisation of goodwill) = $400k Net cash generated in just over 6 months of trading " Dividend of $0.0025 per share declared = $500k debt
Slide 4: FY04 Highlights: Devices Sales
FY04 Highlights €> Platforms for growth were built Devices Sales * Sole source contract for Peak Flow Meters with New Zealand Government signed (3 years) « Richard Thomson Pty. Ltd. appointed as Australian distributor to hospitals, doctors and pharmacies « International Agents appointed - GCC countr
Slide 5: FY04 Highlights: Penthrox Sales
S a 8 i & rai s s oD 2 ae oD E ee 2 S o ‘2 © 2 G2 wo S FY04 Highlights Platforms for growth were built Penthrox Sales * Tasmanian Ambulance and NZDF added to customer list * Common Technical Document (CTD) due in September 2004 « New product applications being developed - Hospitals - GPs - Veterinar
Slide 6: FY04 Highlights: Operations
FY04 Highlights Platforms for growth were built Operations « Key appointments made - Marketing Manager - Regulatory Affairs Manager - GMP Quality Manager = Penthrox production doubled « Penthrox capacity - review completed « Device capacity review completed = Marketing Infrastructure developed - Pro
Slide 7: FY05 Plans
FY05 Plans FY2005 FY2005 Base Case Upside Scenario 2 $000 % of $000 % of Sales Sales Sales 8,180 100 Sales 12,000 100 EBITDA* 2,870 35 EBITDA* 4,560 38 EBIT 2,260 27 _ EBIT 3,480 29 5 a 8 © & rai s s oD 2 ae oD E ee 2 S o ‘2 © 2 G2 wo S NPAT 1,480 18 NPAT 2,400 20 * Excludes Registration costs. Thes
Slide 8: FY05 Plans: Medical Equipment Sales
FY0O5 Plans €5) The Medical Equipment sales have relatively little risk associated with them Base Case Sales Profile Product Forecast " Space Chambers, Peak Flow Meters and Mask (to existing customers and/or contracts) Double in FY0S « Other medical equipment to existing customers Steady Year on Yea
Slide 9: FY05 Penthrox Plans: Research Laboratories
FY05 — Penthrox Plans €3 Significant growth expected in research laboratories Non-USA Market » Use in research laboratories is exempt from registration METHOXYFLURANE pr CK! / a; ~\ : /% mk « Advertising in Leading European Industry Magazine in August/September and December/January issues ae » Follo
Slide 10: FY05 Penthrox Plans: Australian Hospitals and GPs
FY0O5 — Penthrox Plans €5) Australian hospitals and GPs are seen as significant opportunities Budgeted sales may be conservative * Potentially broad scope of applications - Emergency wards - Burns dressing - Post-op wards - Obstetrics - Short painful procedures in doctors’ rooms - Dentists * Market
Slide 11: FY05 Plans: Overseas Penthrox Registration
S a 8 i & rai s s oD 2 ae oD E ee 2 S o ‘2 © 2 G2 wo S FY0O5 Plans Overseas Penthrox sales are dependent on registration 5 + Registrations are being prioritised based on ease of registration, time-to-market, market potential and cost Country Registration Filing Date Initial Target Market Pre - Regis
Slide 12: FY05 Plans: Overseas Penthrox Registration (continued)
S a 8 i & rai s s oD 2 ae oD E ee 2 S o ‘2 © 2 G2 wo S FY0O5 Plans Overseas Penthrox sales are dependent on registration 5 Country Registration Initial Target | Pre - Trials during | Estimated Filing Date Market Registration FY2005 Registration Sales Potential Date South Korea | Q4 2004 Ambulance /
Slide 13: FY05 Plans: Overseas Marketing and Sales Effort
FY0O5 Plans (a) Significant marketing and sales effort is being applied to these overseas opportunities =" NZDF and Dubai Police sales are imminent " Sales and Marketing Plans are being finalised with local agents in all countries « MDI has built considerable product support capability * Product inf
Slide 14: FY05 Plans: Further Registrations
FY05 Plans an) Further registrations will be filed in the second half of FY¥2005, €5 although priorities are still being determined Other Countries under Consideration a S = Country/Region Observation SC 6 UK/EU Dependent on extent of clinics/trials = required L a lran Assessing registration require
Slide 15: FY05 Plans: Veterinary and Mass Disaster Markets
FYO5 Plans (4) Other opportunities being explored are in the veterinary and mass disaster markets Veterinary Markets Application: Adjunct to anaesthesia in animal operations to manage pain on waking and ease animal handling Initial Targets: = Australia and New Zealand Strategy: Commission study by M
Slide 16: FY05 Plans: Production Capacity
5 a 8 © & rai s s oD 2 ae oD E ee 2 S o ‘2 © 2 G2 wo S FY0O5 Plans We have significant scope to increase production capacity with little additional investment Penthrox Plant * Production was doubled in FY2004 = Capacity of current plantis 7 x current output « Additional requirements to achieve capac
Slide 17: Summary
5 a 8 © & rai s s oD 2 ae oD E ee 2 S o ‘2 © 2 G2 wo S Summary The future is very bright. We have three key challenges this year: « Minimise registration timeframes « Convert opportunities to sales as quickly as possible « Plan for the commissioning of a new Penthrox plant just ahead of demand
Medical Developments International — Investor Presentation (September 2004) on 6ix